Study Designed To Evaluate The Long-Term Safety And Efficacy Of Study Drug (Spd503) In Kids With Attention-Deficit/Hyperactivity Disorder
Posted Date: Jan 14, 2020
- Investigator: Melissa Delbello
- Specialties: ADD/ADHD, Psychiatry/Psychology
- Type of Study: Drug
A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator,Dose-optimization Evaluation followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents aged 6 to 17 Years with Attention-deficit/Hyperactivity Disorder
Criteria:
Kids Aged 6 To 17 Years Diagnosed With Adhd With Prior Stimulant Therapy Is Not Suitable, Not Tolerated
Keywords:
Add, Adhd, Children And Adolescents
For More Information:
Veronica Aghera
(513) 558-3314
agherava@ucmail.uc.edu